Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsArizona Medicaid Buprenorphine Prior Auth | OpenPa…
    Ask Trek AI about this page
    ModifiedArizona Complete HealthPolicy AZ.CP.PHAR.289

    Buprenorphine Implant/Injection (Probuphine, Sublocade)

    Customize your policy alerts

    Sign up for Arizona Complete Health Policy AZ.CP.PHAR.289 alerts

    Get alerted when Policy AZ.CP.PHAR.289 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Prior authorization and medical-necessity coverage for Probuphine buprenorphine implants and Sublocade buprenorphine injections for Arizona Medicaid members with opioid dependence or opioid use disorder, including initial and continuation criteria, dose limits, documentation requirements, and exclusions.

    Policy Summary
    PayerArizona Complete Health
    PolicyBuprenorphine Implant/Injection (Probuphine, Sublocade)
    Policy CodePolicy AZ.CP.PHAR.289
    Change TypeClinical criteria change
    Effective DateNov 1, 2019
    Last ReviewFeb 1, 2022
    Next Review DateN/A
    Key ActionSubmit documentation supporting that the member meets all applicable approval criteria.
    SourceLink
    POLICY UPDATE CHANGES

    Probuphine implant criteria were added during the 1Q 2020 annual review.

    The concurrent serious mental illness diagnosis requirement for Sublocade was removed.

    The requirement that members be older than 18 years for Probuphine and Sublocade was removed.

    The policy was clarified to specify that its criteria also apply to Care1st.

    The 1Q 2022 annual review reported no significant clinical changes and updated references.

    2Covered products
    4 implants/6 monthsMaximum Probuphine dose

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    300 mg/month
    Maximum Sublocade dose
    6 monthsApproval duration
    2 setsMaximum Probuphine implant sets
    Arizona MedicaidLine of business

    Coverage Criteria

    Initial Therapy - Probuphine Implant

    Covered when all applicable criteria are met:

    Probuphine Implant

    • Diagnosis and treatment status: Member has a diagnosis of opioid dependence and is currently receiving a maintenance dose of no more than 8 mg/day of oral buprenorphine or buprenorphine-naloxone sublingual tablet or film for 3 months or longer, without supplemental dosing or dose adjustments.≤8 mg/day for ≥3 months
    • Need for implant formulation

      • Qualifying condition: Noncompliance with oral buprenorphine; treatment failure with oral formulations; history of diversion with buprenorphine medication-assisted treatment products; or contraindication or clinically significant adverse effects to oral-formulation excipients.
    • Comprehensive treatment: Member is receiving psychosocial interventions as part of a comprehensive medication-assisted treatment program.
    • Dose limit: Dose does not exceed 4 implants per 6 months.≤4 implants per 6 months

      Approval duration is 6 months.

    Initial Therapy - Sublocade Injection

    Covered when all applicable criteria are met:

    Sublocade Injection

    • Diagnosis and qualifying treatment: Member has a diagnosis of opioid dependence and is currently receiving 8 to 24 mg/day of buprenorphine or buprenorphine-naloxone sublingual tablet or film for 7 days or longer.8–24 mg/day for ≥7 days
    • No supplemental buprenorphine: Member will not receive supplemental oral, sublingual, or transmucosal buprenorphine.None
    • Comprehensive treatment: Member is receiving psychosocial interventions as part of a comprehensive medication-assisted treatment program.

    Continuation Therapy - Probuphine Implant

    Continued coverage requires all applicable criteria to be met:

    Probuphine Implant

    • Qualifying opioid-use condition: Member has not received supplemental, oral, sublingual, or transmucosal buprenorphine or an opioid analgesic since the last approval; or the prescriber documents that opioid use during the last approval period was due to acute pain.
    • Implant-arm restriction: Member has not had prior implants inserted in the contralateral arm and has not previously received two sets of implants, with one set defined as four implants per arm.Maximum 2 sets total

    Continuation Therapy - Sublocade Injection

    Continued coverage requires all applicable criteria to be met:

    Sublocade Injection

    • Qualifying opioid-use condition: Member has not received supplemental, oral, sublingual, or transmucosal buprenorphine since the last approval; or the prescriber documents that opioid use during the last approval period was due to acute pain.

    Other Diagnoses or Indications

    Other diagnoses or indications must meet one of the following alternatives:

    Other diagnoses or indications

    • Existing therapy response: Member is currently receiving the medication through the Centene benefit and documentation supports a positive response to therapy.
    • Off-label review: Refer to the applicable off-label use policy when the diagnosis is not specifically listed under the nonauthorized diagnoses section.

      For Arizona Medicaid, refer to AZ.CP.PMN.53.

    Coverage is not authorized for non-FDA-approved indications that are not addressed in this policy unless sufficient documentation of efficacy and safety is provided in accordance with the applicable off-label use policy, AZ.CP.PMN.53, for Arizona Medicaid.

    Initial Therapy Criteria

    Probuphine Initial Therapy

    Covered when all applicable criteria are met:

    Probuphine initial therapy: Member has opioid dependence; is maintained on no more than 8 mg/day of oral buprenorphine or buprenorphine-naloxone sublingual tablet or film for at least 3 months without supplemental dosing or adjustments; has co-occurring serious mental illness and documented medical justification for inability to continue oral formulations; receives psychosocial interventions as part of a comprehensive medication-assisted treatment program; and does not exceed the dose limit.≤8 mg/day for ≥3 months; ≤4 implants per 6 months

    Members should not be tapered to a lower dose solely to transition to Probuphine. Approval duration is 6 months.

    Sublocade Initial Therapy

    Covered when all applicable criteria are met:

    Sublocade initial therapy: Member has opioid dependence; is receiving 8 to 24 mg/day of buprenorphine or buprenorphine-naloxone sublingual tablet or film for at least 7 days; will not receive supplemental oral, sublingual, or transmucosal buprenorphine; receives psychosocial interventions as part of a comprehensive medication-assisted treatment program; the prescriber checks the Arizona State Board of Pharmacy CSPMP database before each monthly injection; and the dose does not exceed 300 mg per month.

    Continuation and Transition Criteria

    Probuphine Continued Therapy

    Continued coverage requires all listed criteria to be met:

    Probuphine continued therapy

    • Qualifying opioid-use condition: Member has not received supplemental, oral, sublingual, or transmucosal buprenorphine or an opioid analgesic since the last approval; or the prescriber documents that opioid use during the last approval period was due to acute pain.

    Sublocade Continued Therapy

    Continued coverage requires all listed criteria to be met:

    Sublocade continued therapy

    • Qualifying opioid-use condition: Member has not received supplemental, oral, sublingual, or transmucosal buprenorphine since the last approval; or the prescriber documents that opioid use during the last approval period was due to acute pain.

    Product Quantity and Dose Limits

    Quantity Limit
    ProductProbuphine
    Maximum quantity4 implants
    Limit periodPer 6 months
    Quantity Limit
    ProductSublocade
    Maximum dose300 mg
    Limit periodPer month

    Prior Authorization and Provider Requirements

    Documentation Required

    Submit Supporting Documentation

    Submit documentation demonstrating that the member meets all applicable approval criteria for the requested product and treatment phase.

    • Include supporting documentation with the prior authorization request.
    Prior Authorization

    Initial Approval Duration

    Initial requests are approved for 6 months when the applicable product-specific criteria are met.

    • Probuphine approval duration: 6 months.
    • Sublocade approval duration: 6 months.
    Documentation Required

    Clinical Background

    Buprenorphine is a partial opioid agonist used in medication-assisted treatment for opioid dependence or opioid use disorder. Probuphine is a buprenorphine implant for maintenance treatment in clinically stable patients receiving low-to-moderate transmucosal buprenorphine doses. Sublocade is an extended-release buprenorphine injection for moderate-to-severe opioid use disorder after initiation and dose adjustment with transmucosal buprenorphine. Both products are intended for use with counseling and psychosocial support as part of a comprehensive treatment program.

    Definitions and Abbreviations

    Definition
    AbbreviationEVA
    Full termEthylene vinyl acetate
    Source locationAppendix A: Abbreviation/Acronym Key
    Definition
    AbbreviationFDA
    Full termFood and Drug Administration
    Source locationAppendix A: Abbreviation/Acronym Key
    Policy Summary
    PayerArizona Complete Health
    PolicyBuprenorphine Implant/Injection (Probuphine, Sublocade)
    Policy CodePolicy AZ.CP.PHAR.289
    Change TypeClinical criteria change
    Effective DateNov 1, 2019
    Last ReviewFeb 1, 2022
    Next Review DateN/A
    Key ActionSubmit documentation supporting that the member meets all applicable approval criteria.
    SourceLink
    On This Page
    Coverage CriteriaInitial Therapy CriteriaContinuation and Transition CriteriaProduct Quantity and Dose LimitsPrior Authorization and Provider RequirementsClinical BackgroundDefinitions and Abbreviations
    Monitoring and dose limit: Prescriber confirms that the Arizona State Board of Pharmacy Controlled Substance Prescription Monitoring Program database was checked before each monthly injection, and the dose does not exceed 300 mg per month.≤300 mg/month
    8–24 mg/day for ≥7 days; ≤300 mg/month

    Approval duration is 6 months.

    Sublocade Initial Therapy — Two Monthly Initial Doses

    Sublocade initiation requires the following dosing regimen:

    Initial dosing: Administer two initial Sublocade doses of 300 mg subcutaneously, followed by 100 mg monthly maintenance doses.300 mg subcutaneously for each of 2 initial months; then 100 mg monthly

    Sublocade is supplied in prefilled syringes.

    Transition After Probuphine Implants

    Following bilateral Probuphine use:

    Transition after bilateral Probuphine use: Following one Probuphine insertion in each arm, most patients should be transitioned back to a transmucosal buprenorphine-containing product for continued treatment.1 insertion in each arm

    Avoid previously implanted sites because the effects of scarring and fibrosis on effectiveness and insertion safety have not been evaluated.

    Product Quantity Details
    ProductProbuphine buprenorphine implant
    Implants per dose4 implants inserted subdermally in the inner side of the upper arm
    Intended duration6 months
    Product Dose Limit
    ProductSublocade buprenorphine injection
    Initial dosingTwo monthly initial doses of 300 mg subcutaneously
    Maximum dose300 mg per month

    Submit Clinical Records

    Provide clinical records supporting the requested therapy and applicable criteria.

    • Office chart notes
    • Laboratory results
    • Other relevant supporting clinical information
    Documentation Required

    Probuphine Oral-Formulation Justification

    For Probuphine, document co-occurring serious mental illness and medical justification for why the member cannot continue oral buprenorphine formulations.

    • Document noncompliance with oral buprenorphine; treatment failure; a history of diversion with buprenorphine MAT products; or contraindications or clinically significant adverse effects to oral-formulation excipients.
    Documentation Required

    Document CSPMP Monitoring

    Document that the prescriber checks the Arizona State Board of Pharmacy Controlled Substance Prescription Monitoring Program (CSPMP) database as required.

    • For initial Sublocade requests, confirm the CSPMP was checked before each monthly injection.
    • For continuation requests, document that CSPMP checks are regularly occurring.
    Documentation Required

    Document Acute-Pain Opioid Use

    If opioids were used during the prior approval period, document that the use was for a diagnosis of acute pain when applicable.

    • For continuation requests, provide prescriber documentation acknowledging that opioid use during the last approval period was due to acute pain.

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Unsupported block type: prior_auth

    Definition
    AbbreviationMAT
    Full termMedication-assisted treatment
    Source locationAppendix A: Abbreviation/Acronym Key